Post-BMT subjects have an increased bone fracture risk. Additionally, several factors were associated with osteopenia and osteoporosis in these individuals. We aimed to identify other factors associated with osteopenia and osteoporosis in allogeneic post-BMT subjects. We conducted a cross-sectional study with 47 allogeneic post-BMT subjects. Serum 25-hydroxyvitamin D (25(OH)D), parathyroid hormone, ferritin, vitamin B 12 , insulin, glucose, cholesterol and triglyceride levels were measured. Insulin resistance and secretion were estimated through the homeostatic model assessment for insulin resistance (HOMA-IR) and homeostatic model assessment for b-cell function (HOMA-B) , respectively. A bone densitometry (BMD) was also obtained. The median time after BMT was 47.7 (12-115) months. Osteoporosis was identified in 17.0% of the subjects and osteopenia in 19.7%. The mean serum ferritin (P ¼ 0.002), insulin (Po0.0001), glucose (P ¼ 0.003) and triglyceride (P ¼ 0.018) levels were higher in individuals with osteopenia/osteoporosis. HOMA-IR (Po0.0001) and HOMA-B (Po0.0001) were increased in post-BMT subjects with osteopenia/osteoporosis. There was no other factor associated with the outcome. After adjustments ferritin, serum 25(OH)D and HOMA-IR remained independently associated with osteopenia/osteoporosis; however triglycerides no longer were. In conclusion, in the present study, low serum 25(OH)D levels, high serum ferritin levels and insulin resistance were associated with osteopenia/osteoporosis in post-BMT subjects.
Introduction
Allogeneic BMT is an established therapy for several medical conditions such as leukemia, myelodysplastic syndrome, aplastic anemia, immunodeficiency syndromes and hemoglobinopathies. Many individuals survive for decades after BMT and are presumably cured. However, as the post-transplant life expectation rises the post-transplant comorbidities also do. Osteopenia and osteoporosis have been reported after BMT in several studies [1] [2] [3] [4] and the posttransplant subjects have a higher bone fracture risk when compared with a non-transplant population. 5 There is a decrease in bone formation with an increase in bone resorption in the immediate post-BMT period. This fast bone loss continues during the first year after the transplantation and it stabilizes thereafter. 5 The mechanisms of post-BMT bone loss are not completely understood, but they are apparently multifactorial. After BMT, cellular and cytokine-mediated BM function is impaired, the osteoprogenitors are damaged, the osteocyte viability is diminished and there is cytokine release. [6] [7] [8] The receptor activator of nuclear factor kb ligand and its receptor may also have a role through the up regulation of IL7. 9 Regardless of its mechanisms, there are a few risk factors for allogeneic post-BMT bone loss: glucocorticoid use, high-dose chemotherapy, whole-body irradiation, hypogonadism, GVHD and growth hormone deficiency in children. 10 Besides the classical risk factors there are other possible ones: Rakel et al. have recently published a study showing diabetes mellitus as a risk factor for bone fractures in recipients of solid organ transplantation, 11 and increased serum ferritin levels have also been reported as a risk factor for bone fractures in patients with thalassemia. 12 Nevertheless, until the present moment we do not know whether diabetes mellitus or impaired glucose metabolism, and high serum ferritin levels, have some effect in post-BMT osteopenia and osteoporosis. The aim of this study was to identify factors associated with osteopenia and osteoporosis in the recipients of allogeneic BMT.
Materials and methods
Study design and population A cross-sectional study was conducted at the Hematology and Bone Marrow Division of the Hospital de Clı´nicas de Porto Alegre, in the city of Porto Alegre, south of Brazil. All the subjects, who had received allogeneic BMT at least one year earlier and were attending the long-term follow-up ambulatory clinic, were enrolled in this study. No subject was excluded and it was conducted from May 2005 to May 2006. The study was approved by the Ethics Committee of Hospital de Clı´nicas de Porto Alegre, and all the individuals provided an informed consent term.
Procedures
After enrollment each subject had his/her medical history evaluated through a questionnaire and medical record review. Data about age, number of months after BMT, medications, comorbidities, tobacco or alcohol use, induction chemotherapy, and TBI, were obtained. Sex, weight, height, skin phototype and calcium ingestion were evaluated in the same day, by two members of the research team (GAMF and HLM). Skin phototype was classified from I to VI, as proposed by Fitzpatrick. 13 The skin phototype measurement was used to ensure a more precise skin color measurement, as 50.2% of the Brazilian population are considered to be of mixed race.
14 Calcium intake was estimated through the 24-h diet recall method. 15 Functional capability was subjectively evaluated as: very good, good, regular and bad. Glomerular filtration rate was estimated by the Modification of Diet in Renal Disease abbreviated equation. 16 Insulin resistance and secretion were estimated through the Homeostatic Model Assessment for insulin resistance (HOMA-IR) and Homeostatic Model Assessment for b-cell function (HOMA-B), respectively. 17 Blood samples were collected between 13:00 and 14:00 hrs, after a fasting of at least 4 h. All samples were frozen at À70 1C and analyzed at the same time.
Assays
Serum 25-hydroxyvitamin D (25(OH)D) levels were assayed by chemoluminescence (LIAISON -25(OH)vitamin D, Diasorin Inc, Stillwater, MN, USA; intra-assay coefficient of variation (CV) was 2%). Serum intact parathyroid hormone (PTH), insulin, ferritin and vitamin B 12 levels were assayed by electrochemiluminescence (Elecsys-Modular E-170, Roche Diagnostics, Indianapolis, IN, USA; intra-assay CV was 2.5%). Serum creatinine, glucose, total cholesterol, high-density lipoprotein cholesterol and triglycerides levels were measured by routine methods at HCPA (Modular-P, Roche Diagnostics).
Bone densitometry
Bone densitometry (BMD) was measured by dual energy X-ray absorptiometry using a densitometer (Expert-XL; Lunar Corporation; Madison, WI, USA). It was measured at lumbar spine (vertebrae L1-L4) and at proximal femur (femoral neck, trochanter and Ward's triangle), in all subjects. The precision of the method (CV) was 1.0% at both locations. The diagnosis of osteopenia and osteoporosis was based on the World Health Organization definition: osteoporosis was defined as a BMD value pÀ2.5 (s.d. below the mean value of a young healthy population, and osteopenia was defined as a BMD value between, but not including, À2.5 s.d. and À1.0 s.d. 18 Osteopenia/osteoporosis was diagnosed when the t-score was lower than À1.0 in any given site.
Statistical analysis
The prevalence of osteoporosis and osteopenia were calculated. The association with risk factors was evaluated using Student's t-, Mann-Whitney's, w 2 and Fisher's Exact tests. A difference of Po0.05 was regarded as significant. A binary logistic regression was used to evaluate factors associated with osteopenia and osteoporosis. The variables with an asymmetrical distribution were transformed into their natural logarithm to enter in the equation. Data were analyzed using the SPSS statistics package for Windows version 16.0 (SPSS Inc, Chicago, IL, USA).
Results
In total, from July 1995 to May 2005, 155 individuals were transplanted at the Hematology and Bone Marrow Division of the Hospital de Clı´nicas de Porto Alegre. Of those 87 died and six were lost to follow up. Sixty-two subjects were eligible for the study and were invited to participate. One subject refused and 14 subjects were unable to complete the BMD examination.
The baseline characteristics for this population are described in Table 1 . Their mean age was 38.6 (range 14-57) years and the mean time elapsed since the transplant was 47.7 (range 12-115) months (Table 1) . Osteoporosis was identified in 17.0% of the subjects and osteopenia in 46.8%, in one or both sites.
There was no association between age, phototype, time elapsed since BMT, clinical diagnoses, tobacco or alcohol use, body mass index (BMI), glomerular filtration rate, international normalized ratio (INR) for blood coagulation tests, functional capability, calcium intake, glucocorticoid use, induction chemotherapy, TBI, GVHD and osteopenia plus osteoporosis (osteopenia/osteoporosis). There was also no association with osteopenia/osteoporosis and the serum PTH, serum 25(OH)D and vitamin B 12 levels. However, serum ferritin levels were higher in subjects with osteopenia/osteoporosis. These results are shown in Table 1 .
Mean serum insulin, glucose and triglycerides level were higher in individuals with osteopenia/osteoporosis. Insulin resistance (HOMA-IR) was also increased and insulin secretion was impaired (HOMA-B) in post-BMT subjects with osteopenia/osteoporosis. There was no difference in serum cholesterol levels between the groups. These results are shown in Table 2 .
The factors associated with osteopenia/osteoporosis were studied in a binary logistic regression model. Serum 25(OH) levels were included in the model because of its importance for bone health. Serum ferritin levels, serum 25(OH)D levels and the HOMA-IR were independently associated with osteopenia/osteoporosis; however, serum triglyceride levels no longer remained associated with osteopenia/ osteoporosis after the adjustments, as shown in Table 3 .
Discussion
The morbidity faced by subjects who had received an allogeneic BMT is an established issue and it increases as post-transplant life expectation rises. Despite the fact that the bone resorption stabilizes 1 year after BMT, many studies have reported high osteopenia prevalence: Kerschan-Schindl et al. studied 22 individuals in Vienna, Austria, more than 5 years after BMT and they found a 28% prevalence of osteopenia in lumbar spine and a 48% prevalence of osteopenia in femoral neck. 3 Another study conducted in Geneva, Switzerland, enrolled 54 subjects 60.1±5.6 months after allogeneic BMT and also found a high osteopenia prevalence (43%).
1 So, the high prevalence of osteopenia (19.2%) and osteoporosis (17%) found in our study is not surprising.
In this study there was no association between osteopenia/osteoporosis and age, phototype, time elapsed since BMT, clinical diagnoses, tobacco or alcohol use, BMI, glomerular filtration rate, international normalized ratio, functional capability, calcium intake, glucocorticoid use, induction chemotherapy, TBI, GVHD, and serum PTH, 25(OH)D and vitamin B 12 levels. Not all studies were able to identify factors associated with osteopenia. Castaneda et al. evaluated 27 women after menopause and did not find association between bone loss and the studied variables: age, BMI, number of months after transplantation, number of months after menopause, PTH and 1,25 dihydroxyvitamin D.
2 Additionally, Shimmer et al. also did not find association between hypogonadism, gender and BMI, and the decrease of the BMD in 64 subjects evaluated 4.2 years after BMT. 4 Several factors may have contributed to our negative results: first, all subjects had more than 1 year after the transplant when the rapid bone resorption decreases. Second, international normalized ratio, used to assess vitamin K status, is not the best marker for it. Third, the daily calcium intake was below the recommended allowance in both groups. Fourth, TBI was used in only a few subjects. Finally, the negative results regarding an association between glucocorticoid use and osteopenia/osteoporosis may be because of the fact that only the current glucocorticoid use was analyzed, and only two patients were on these drugs. This was the better approach when we considered the glucocorticoid use as a confounding factor for insulin resistance; however, the total amount of glucocorticoid would have been better for an association with osteopenia/osteoporosis. Unfortunately, we were unable to retrieve the past steroid use. Increased serum ferritin has been reported as associated with fractures and decreased bone mass in some studies. 12, 19 Serum ferritin levels have been thought to reflect the body iron stores; however, it is also a secreted by-product of intracellular ferritin synthesis. 20 This last process is increased in some inflammation states as chronic diseases. It would be possible that the high serum ferritin levels found in our study reflected both situations. Additionally, both mechanisms could be implicated in the association between high mean serum ferritin levels and osteopenia/ osteoporosis. Fung et al. reported that for serum ferritin levels over 2000 ng/ml subjects with more blood transfusions had a greater fracture risk which could be due to iron overload. 12 Nevertheless, the presence of inflammatory proteins such as IL7 has been linked to bone loss, and the high serum ferritin levels could be a marker of chronic inflammation. 20 No matter the main explanation, in this study the serum ferritin levels were higher in subjects with osteopenia/osteoporosis.
The higher fracture incidence in subjects with type II diabetes mellitus is well known. The Rotterdam study included 792 elderly individuals with type II diabetes mellitus and 5863 non-diabetic controls, and it found a hazard ratio of 1.33 (95% CI 1.00-1.77) for fractures in the diabetic group. 21 In addition, the Rancho Bernardo Study reported that metabolic syndrome was not only associated with a lower BMD, but it was also associated with an increased incidence of osteoporotic fractures. 22 Hyperglycemia may have a direct adverse effect on bone metabolism because glucose enhances osteoclast activity in vitro. 23 One study conducted with 238 subjects who had received their first solid organ transplantation and 873 controls showed an odds ratio of 1.94 (95% CI 1.5-2.6) for fracture on individuals with pre-transplant diabetes. 11 To our knowledge our study is the first one to evaluate the association between insulin resistance and insulin secretion and osteopenia/osteoporosis in post-BMT subjects. Both measurements were strongly associated with the outcome. We also found higher serum insulin, glucose and triglycerides levels in individuals with osteopenia/osteoporosis.
It is interesting that, similar to our study, the earlier described solid organ transplantation study did not find an association between the glucocorticoid use and fractures. 11 Moreover, in this study the steroid use was evaluated as cumulative doses and as a dichotomous variable.
When we studied the associated factors in a logistic regression model serum ferritin levels, serum 25(OH)D levels and insulin resistance were independently associated with osteopenia/osteoporosis; however, serum triglycerides levels no longer remained associated with it. This model is very important because it shows that the association between insulin resistance and osteopenia/osteoporosis is not because of the iron overload or vitamin D deficiency, although hypovitaminosis D has been proposed by some authors to explain diabetics' increased risk of fracture.
Vitamin D deficiency was associated with osteopenia/ osteoporosis after adjustments in this study. Nevertheless, the association between serum triglyceride levels and osteopenia/osteoporosis disappeared after corrections in this study. This result is in accordance with the National Table 3 Model of binary logistic regression for possible factors associated with osteopenia and osteoporosis (n ¼ 47) Health and Nutritional Examination Survey III that found no association between lipids and BMD measurements after adjustments. 24 Our logistic regression model has some strength: it is logical and has a very significant constant. Nevertheless, we should be cautious with the odds ratios interpretation as regression models with small samples tend to skew their distributions toward values far above the true odds ratio. However, the lower limits of the confidence interval in small samples regression are generally correct and the true odds ratio are much closer to the lower 95% CI limits than in larger regression models. 25 In our study we interpreted our logistic regression model adjusted factors just as independently associated with osteopenia/osteoporosis or not.
Osteopenia and osteoporosis are major problems during the follow-up of BMT subjects; moreover, they have an increased fracture risk and it is magnified because of these individuals' longer life span. The identification of associated factors that could be possibly reverted is relevant for the clinical practice. Our study had identified low serum 25(OH)D levels, high serum ferritin levels and insulin resistance (HOMA-IR) as factors associated with osteopenia/osteoporosis in post-BMT subjects. More studies should be conducted to clarify whether they are risk factors for low bone mass and to learn their reversion would improve bone density and the fracture risk. Until then, we should be careful with all health aspects of subjects with a previous BMT.
